Conflict 2: Inadequate Monitoring
The individual pharmaceutical companies that participate in IMI provide payments in kind instead of money. But whether and how they do this remains unclear to the public. So who actually monitors the industry?
What the public is not informed about, however, is how much the individual pharmaceutical companies contribute to the individual IMI projects. Because EFPIA officially functions as an IMI project partner, it is only required to report its contribution, IMI stated when contacted by the journalists. In Brussels, officials in the EU executive point out that because the pharmaceutical companies receive no funds from the Commission, the public has no right to monitor these firms. They also note that the individual companies' contributions are confidential.
But even the control committee that represents the EU member states within the IMI was not given access to EFPIA contributions, reports a member of the committee. In a 2013 report on IMI, the European Parliament criticized the fact that the European Court of Auditors could not audit the payments in kind by industry partners, even though they appeared in IMI's financial statement.
- TMN/ Beyond